Emerging treatments
Angiotensin II
A randomized controlled trial found that angiotensin II increased blood pressure in patients with vasodilatory shock not responsive to high-dose vasopressors.[205] The Food and Drug Administration (FDA) has approved angiotensin II for the treatment of hypotension in adults with septic or other distributive shock.
New antibiotics
Meropenem/vaborbactam is a carbapenem/beta-lactamase inhibitor combination that has demonstrated higher clinical cure rates versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE), among other infections.[206] Meropenem/vaborbactam is approved by the FDA for treatment of adults with complicated urinary tract infections. The FDA has also approved two cephalosporin/beta-lactamase inhibitor combination antibiotics (i.e., ceftazidime/avibactam and ceftolozane/tazobactam) for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired and ventilator-acquired bacterial pneumonia.
Extracorporeal membrane oxygenation (ECMO)
ECMO may be useful in sepsis-induced severe acute respiratory distress syndrome when conventional mechanical ventilation fails. Availability of ECMO is limited to experienced centers with the infrastructure in place to support its use.[3]
Use of this content is subject to our disclaimer